Acrux Limited (AU:ACR)
ASX:ACR
Want to see AU:ACR full AI Analyst Report?
ACR Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.03
Previous CloseN/A
Volume88.57K
Average Volume (3M)120.95K
Market Cap
AU$4.52M
Enterprise ValueAU$7.21M
Total Cash (Recent Filing)AU$863.00K
Total Debt (Recent Filing)AU$3.63M
Price to Earnings (P/E)9.3
Beta0.19
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding410,608,520
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset-light Licensing Business ModelAn IP/licensing model keeps capital intensity low and shifts commercialization costs to partners. That structural setup preserves cash, enables scalable royalty income and milestone upside, and reduces the firm's need for large commercial investments over the next 2-6 months.
Very High Reported Gross Margin At Product LevelA reported 100% gross margin implies licensing or low-cost delivery of products versus sales price, reflecting strong product/IP economics. Durable high gross margins give room to absorb SG&A and support future profitability if operating losses are contained or converted.
Notable Recent Revenue GrowthSustained double-digit revenue gains indicate growing partner sales or expanding licensing receipts. Continued top-line growth supports scaling royalties and validates market demand for topical testosterone therapies, improving midterm revenue visibility if partners continue execution.
Bears Say
High Financial LeverageA debt-to-equity ratio above 3 indicates substantial leverage that increases interest and refinancing burden. High leverage reduces financial flexibility, elevates solvency risk if revenue or milestone timing falters, and can constrain strategic choices over the coming months.
Persistent Net Losses And Negative ProfitabilityRecurring net losses and negative return on equity show the company has yet to convert gross economics into operating profitability. Sustained losses deplete equity, force dependence on external funding, and undermine long-term viability unless operational trends reverse.
Negative Operating Cash Flow And Cash Generation RiskNegative operating cash flow means core operations do not fund activities, making the firm reliant on financing or partner milestone payments. Close alignment of free cash flow to net losses limits liquidity buffers and raises funding and execution risk in the medium term.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$4.52M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 21, 2026 which is in 113 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 410,608,520 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-211.88%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited (ACR) is a biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative drug delivery technologies and pharmaceutical products. The company operates primarily in the healthcare sector, focusing on transdermal delivery systems, which enable medications to be absorbed through the skin. Acrux's core products include various transdermal patches and formulations designed to improve patient adherence and therapeutic outcomes in areas such as hormone replacement therapy and pain management.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---